|
WO2021041276A1
|
|
Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors
|
|
WO2020139855A2
|
|
Chimeric signal peptides for protein production
|
|
WO2020124039A1
|
|
Anti-human csf-1r antibody and uses thereof
|
|
EP3604288A1
|
|
Regioselective one-step process for synthesizing 2-hydroxyquinoxaline
|
|
TW202005983A
|
|
Anti- human PD-L1 antibodies and their uses
|
|
TW202016145A
|
|
Humanized antibodies against human tim-3 and uses thereof
|
|
CN112135637A
|
|
Antibody PROTAC conjugates
|
|
TW201938789A
|
|
A method of in vitro diagnostic for prediction of drug efficacy
|
|
TWI689594B
|
|
Multiplex quantitative method for microrna
|
|
WO2019133752A1
|
|
A method for predicting drug efficacy
|
|
AU2018397483A1
|
|
Heterocycle compounds as Tyro3, Axl and Mertk (TAM) family of receptor tyrosine kinase inhibitors
|
|
TW201928051A
|
|
Host cells with enhanced protein expression efficiency and uses thereof
|
|
TW201904998A
|
|
Asymmetric heterodimeric FC-SCFV fusion anti-GLOBO H and anti-CD3 bispecific antibody and its use in cancer therapy
|
|
CN111093702A
|
|
Asymmetric heterodimeric Fc-ScFv fusion antibody format with engagement and activation of target cell-dependent T cells for cancer therapy
|
|
WO2018232349A1
|
|
Antibody-drug conjugates containing anti-globo h antibodies and uses thereof
|
|
WO2018218068A1
|
|
Humanized antibodies against globo h and uses thereof in cancer treatments
|
|
CN111093659A
|
|
Medicine for resisting cancer dryness
|
|
JP2019154414A
|
|
Alpha-enolase specific antibodies and methods of using the same
|
|
TW201827083A
|
|
Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions
|
|
TWI657824B
|
|
A universal vaccine against influenza
|
